Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

Jun Masuda; Hitomi Sakai; Junji Tsurutani; Yuko Tanabe; Norikazu Masuda; Tsutomu Iwasa; Masato Takahashi; Manabu Futamura; Koji Matsumoto; Kenjiro Aogi; Hiroji Iwata; Mari Hosonaga; Toru Mukohara; Kiyoshi Yoshimura; Chiyo K Imamura; Sakiko Miura; Toshiko Yamochi; Hidetaka Kawabata; Hiroyuki Yasojima; Nobumoto Tomioka; Kenichi Yoshimura; Toshimi Takano

doi:10.1136/jitc-2023-007126

Citation Tools

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Masuda J, Sakai H, Tsurutani J, et al

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)

Journal for ImmunoTherapy of Cancer 2023;11:e007126. doi: 10.1136/jitc-2023-007126

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password